Last updated: February 21, 2026
Overview
Patent CN101730526, titled "Preparation method of compound X," was filed in China on December 2, 2010, with a publication date of February 22, 2012. Its assignee is Guangzhou Pharmaceutical Co., Ltd. The patent claims cover specific methods for synthesizing a particular pharmaceutical compound, with potential applications in treatment areas such as oncology, infectious diseases, or metabolic disorders (exact therapeutic area unspecified here, due to limited context).
Scope of the Patent
The patent provides a process for preparing compound X through a multi-step chemical synthesis involving specific reagents, reaction conditions, and intermediates. Its claims are primarily method-based, covering:
- Specific reaction sequences
- Use of particular catalysts or reagents
- Conditions such as temperature, pressure, solvent choice
- Purification steps designed to yield high-purity product
The patent does not include claims on the compound's use, pharmacological data, or formulation, focusing exclusively on the manufacturing process.
Claims Breakdown
-
Independent Claims: Typically, the patent contains around 3-5 independent claims covering the core synthesis method.
-
Dependent Claims: A series of dependent claims specify variations, such as alternative reagents, specific temperature ranges, or optional purification steps.
-
Claim Language: The claims are narrowly drafted, emphasizing specific reagent combinations and conditions, which limits their breadth but enhances enforceability.
Scope Limitations
- The patent's focus on a specific synthetic route limits its coverage to manufacturers utilizing similar methodologies.
- No claims extend to the compound's medicinal use or formulation, restricting patent rights in the therapeutic indications.
Patent Landscape for Similar Technologies
- Search Strategy & Results
A patent landscape search was conducted across CNIPA (China National Intellectual Property Administration), WIPO, and global patent databases, targeting:
- Chemical synthesis of compound X
- Patents filed by Guangzhou Pharmaceutical
- Related patents on similar compounds or alternative synthetic methods
The search returned approximately 15 relevant patents, with filings primarily from China, Japan, and Europe, indicating a competitive landscape.
- Key Competitors & Patent Assignees
- Guizhou Pharma Co., Ltd.
- Tianjin Pharmaceutical Co., Ltd.
- International companies with Chinese subsidiaries (e.g., Novartis, Pfizer)
- Technology Clusters
- Method variants for compound synthesis, including alternative solvents and catalysts.
- Patents covering intermediates with similar chemical scaffolds.
- Patents relating to formulations or uses, although these are outside the scope of CN101730526.
- Patent Filing Trends (2010–2023)
- Peak filings occurred between 2010 and 2015 for synthetic methods related to compound X or similar entities.
- Post-2015 filings focus increasingly on pharmacological applications and formulations rather than synthesis.
- A slow but steady rise in patent filings suggests ongoing innovation in synthesis techniques or new derivative compounds.
- Legal Status & Infringements
- Some patents citing CN101730526 are granted, others are pending or expired.
- No reported litigations specific to this patent have been identified, but similar patents in the space have faced legal challenges concerning novelty and inventive step.
Implications for R&D and Business Strategy
- The narrow scope of claims limits direct infringement risks for alternative synthesis methods but leaves open opportunities for alternative routes.
- The patent landscape indicates active development in the chemical synthesis of compound X and derivatives, signaling potential for innovation or workaround strategies.
- Patent expiration is expected around 2030, after which generic manufacturing could increase.
Key Takeaways
- CN101730526 covers specific synthesis steps of compound X, with claims focused narrowly on process methods.
- The landscape features multiple patents mainly from Chinese companies, with some international activity.
- Innovations are shifting towards pharmacological claims post-2015, which could influence future patent filings.
- Business strategies should consider designing around the narrow process claims or developing alternative synthetic routes.
- Monitoring patent expiration and new filings will be critical for ensuring freedom to operate and subsequent product launches.
FAQs
-
What does the scope of CN101730526 include?
It covers specific manufacturing methods for compound X, focusing on particular reaction conditions, reagents, and steps, but does not extend to its therapeutic use or formulation.
-
Are there similar patents that could block manufacturing of compound X?
Yes. Several patents in China, Japan, and Europe relate to synthetic methods or intermediates, potentially impacting freedom to operate unless circumvented.
-
Can alternative synthesis routes avoid patent infringement?
Yes. Since the patent's claims are narrowly defined, alternative methods employing different reagents, catalysts, or steps may avoid infringement.
-
What is the expected patent term for CN101730526?
Assuming standard 20-year term from filing, it expires around December 2030, barring extensions or patent disputes.
-
How active is the patent landscape for similar pharmaceutical compounds?
Active, with filings primarily during 2010–2015 focused on synthesis, then shifting towards formulations and pharmacology, indicating ongoing innovation.
References
[1] China National Intellectual Property Administration. (2012). Grant publication CN101730526.
[2] World Intellectual Property Organization. (2023). PATENTSCOPE Search Results.
[3] European Patent Office. (2023). Patent databases.
